l-Asparaginase: a feasible therapeutic molecule for multiple diseases
This note highlights our understanding and thinking about the feasibility of l-asparaginase as therapeutics for multiple diseases. l-asparaginase enzyme (l-asparagine amidohydrolase, EC 126.96.36.199) is prominently known for its chemotherapeutic application. It is primarily used in the treatment of acute lymphoblastic leukemia in children. It is also used in the treatment of other forms of cancer Hodgkin disease, lymphosarcoma, acute myelomonocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, reticulosarcoma and melanosarcoma (Lopes et al. Crit Rev Biotechnol 23:1–18, 2015). It deaminates l-asparagine present in the plasma pool causing the demise of tumor cell due to nutritional starvation. The anti-tumorigenic property of this enzyme has been exploited for over four decades and evidenced as a boon for the cancer patients. Presently, the medical application of l-asparaginase is limited only in curing various forms of cancer.
Keywordsl-asparaginase Malignance Autoimmune disease Infectious disease Therapeutic
Authors are thankful to National Institute of Technology, Raipur (CG), India for providing facility, space and resources for this work.
Compliance with ethical standards
Conflict of interest
The authors have declared no conflict of interest.
- Gieldanowski J (1976) Studies on the immunosuppressive and anti-inflammatory action of L-asparaginase. Arch Immunol Ther Exp (Warsz) 24:243–247Google Scholar
- Reiff A, Zastrow M, Sun BC et al (2001) Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase. Clin Exp Rheumatol 19:639–646Google Scholar